Increlex

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles, Peter Bang, Children's Hospital Medical Center, Cincinnati

Conditions

Chronic Liver DiseaseGrowth FailureGrowth Hormone ResistenceShort StatureType 1 Diabetes MellitusX-linked Severe Combined Immunodeficiency (XSCID)

Phase 1

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

TerminatedNCT00490100

National Institute of Allergy and Infectious Diseases (NIAID)Growth Failure, Growth Hormone Resistence, X-linked Severe Combined Immunodeficiency (XSCID)

Start: 2007-06-30End: 2012-12-31Updated: 2015-07-03

IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

CompletedNCT02636270

Children's Hospital Medical Center, CincinnatiShort Stature

Start: 2015-12-21End: 2022-12-01Updated: 2024-02-28

Unknown Phase

Increlex Treatment of Children With Chronic Liver Disease and Short Stature

WithdrawnNCT01314508

University of California, Los AngelesChronic Liver Disease, Growth Failure

Start: 2011-06-01Updated: 2026-04-14

IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations

CompletedNCT01588093

Peter BangType 1 Diabetes Mellitus

Start: 2011-04-30End: 2011-09-30Updated: 2012-04-30